A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Germline missense mutations affecting a single BRCA2 allele predispose humans to cancer. Here we identify a protein-targeting mechanism that is disrupted by the cancer-associated mutation, BRCA2(D2723H), and that controls the nuclear localization of BRCA2 and its cargo, the recombination enzyme RAD51. A nuclear export signal (NES) in BRCA2 is masked by its interaction with a partner protein, DSS1, such that point mutations impairing BRCA2-DSS1 binding render BRCA2 cytoplasmic. In turn, cytoplasmic mislocalization of mutant BRCA2 inhibits the nuclear retention of RAD51 by exposing a similar NES in RAD51 that is usually obscured by the BRCA2-RAD51 interaction. Thus, a series of NES-masking interactions localizes BRCA2 and RAD51 in the nucleus. Notably, BRCA2(D2723H) decreases RAD51 nuclear retention even when wild-type BRCA2 is also present. Our findings suggest a mechanism for the regulation of the nucleocytoplasmic distribution of BRCA2 and RAD51 and its impairment by a heterozygous disease-associated mutation.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1545-9985
Volume Title
Publisher
Publisher DOI
Rights
Sponsorship
Medical Research Council (G0600332)
Medical Research Council (G1001521)
Medical Research Council (G1001522)
Medical Research Council (G0700651)
Wellcome Trust (089703/Z/09/Z)
MRC (MC_UU_12022/8)